Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Depreciation & Amortization (CF) (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) rose 2.26% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.3 million, a 12.75% increase, with the full-year FY2025 number at $8.3 million, up 12.75% from a year prior.
  • Depreciation & Amortization (CF) was $2.0 million for Q4 2025 at Kymera Therapeutics, down from $2.1 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.1 million in Q3 2025 to a low of $485000.0 in Q1 2021.
  • A 5-year average of $1.2 million and a median of $893000.0 in 2023 define the central range for Depreciation & Amortization (CF).
  • Peak YoY movement for Depreciation & Amortization (CF): soared 123.01% in 2024, then increased 2.26% in 2025.
  • Kymera Therapeutics' Depreciation & Amortization (CF) stood at $689000.0 in 2021, then grew by 18.72% to $818000.0 in 2022, then rose by 8.92% to $891000.0 in 2023, then skyrocketed by 123.01% to $2.0 million in 2024, then increased by 2.26% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Depreciation & Amortization (CF) are $2.0 million (Q4 2025), $2.1 million (Q3 2025), and $2.1 million (Q2 2025).